Showcasing major breakthroughs in cancer care from worldwide clinical trials, Project Oncology® educ
Host: Jacob Sands, MD Guest: Aaron Lisberg, MD Docetaxel alone or in combination w
Host: Jacob Sands, MD Guest: Aaron Lisberg, MD Unfortunately, brain metastases are
Host: Jacob Sands, MD Guest: Alex Spira, MD, PhD, FACP Valemetostat is a novel the
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Thomas Egenod, MD In an effort to
Guest: Cheryl Maier MD, PhD Heparin resistance occurs when patients don’t respond to a
Guest: Michael Gonzalez, PhD, MSc New research on the molecular mechanisms behind idio
Guest: Michele Lambert, MD, MSTR New treatments are on the horizon for patients with i
Host: Jacob Sands, MD Guest: Marina Garassino, MD Datopotamab deruxtecan (Dato-DXd
Guest: Mateo Bustamante Idiopathic multicentric Castleman disease (iMCD) is a rare, li
Guest: Joshua Brandstadter, MD, PhD, MSc Castleman disease is difficult to diagnose an
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Hope S. Rugo, MD, FASCO While endo
Host: Jennifer Caudle, DO Guest: Virginia Kaklamani, MD Guest: Anne O'Dea, MD
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Erika Hamilton, MD The ELECTRA tri
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Mary Frances McMullin, MD The MOME
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Douglas Tremblay, MD Based on thre
Host: Gates B. Colbert, MD Guest: Ryan Cassaday, MD According to the available lon
Host: Matt Birnholz, MD The SIMPLIFY-2 trial compared the efficacy of momelotinib to b
Guest: Betsy O'Donnell, MD Plasma cell disorders range from multiple myeloma to t
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Joshua E. Reuss, MD The phase 2 IC
Host: Saad Z. Usmani, MD, MBA, FACP Guest: Joshua Richter, MD Guest: Ashley Steinberger,
